Henry Schein (HSIC) has been under the limelight with several notable occurrences. The firm has expanded its deal with
Curodont and
vVARDIS, reshaping its tech-enabled margin story and shifting its minimally invasive dental strategy. It secured US exclusive rights to
drill-free cavity treatment, which might alter investor responses. Meanwhile, Q3 earnings beat estimates leading to upward revision of its 2025 sales guidance, which was coupled with strong earnings.
Ilex Capital Partners UK LLP and
SVB Wealth LLC took significant positions in the company, while Gabelli Funds LLC reduced shares. HSIC also extended its strategic partnership agreement and launched
Henry Schein One's Workflow. The firm saw various investor responses, with gains after a raised 2025 outlook and unveiling of a new dental AI tool, but also witnessed drops. The shares witnessed a five-year earnings decline, prompting bearish profitability narratives. The firm recently participated in an investor conference and expanded its
SolutionsHub with
Colaborate while increasing US$750 million buyback.
Henry Schein HSIC News Analytics from Mon, 05 May 2025 07:00:00 GMT to Fri, 12 Dec 2025 14:19:40 GMT -
Rating 9
- Innovation 5
- Information 8
- Rumor -4
